Linked Life Data

9389914

Source:http://linkedlifedata.com/resource/pubmed/id/9389914

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1997-12-12
pubmed:abstractText
The purpose of this study was to evaluate tumour response and toxicity to ifosfamide and continuous infusion etoposide in metastatic or locally advanced soft tissue sarcoma, with dose escalations under G-CSF (granulocyte colony-stimulating factor) support. Of 92 eligible patients (median age 51 years), 85% had tumours of high-grade malignancy and 82% had metastatic disease. Chemotherapy, the baseline dose, consisted of etoposide 600 mg/m2 as a 72 h infusion and ifosfamide 1500 mg/ m2/day for 3 days, followed by G-CSF support (VIG regimen). Stepwise 10% dose escalations were performed depending on haematological toxicity. For patients considered operable after induction chemotherapy, surgical resection of all identifiable residual tumour was attempted. Complete and partial response rates were 11% and 31%, for an overall response rate of 42% (95% CI 31-52%). Forty-eight per cent of courses were dose escalated by a median of 20%. Complete responders had significantly higher, and patients with progressive disease had significantly lower, dose levels than other patients. None of 20 patients with liver metastases responded despite high dose levels. Compared to a preceding pilot study, the addition of G-CSF led to significantly higher dose levels, improved schedule adherence and less haematological toxicity, but no apparent increase in response rate. In view of the modest dose of ifosfamide applied in this study, it is possible that the prolonged infusion of etoposide made a significant contribution to the regimen's antitumour activity, although this can only be determined definitively in a randomised study.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0959-8049
pubmed:author
pubmed:issnType
Print
pubmed:volume
33
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1551-8
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:9389914-Adolescent, pubmed-meshheading:9389914-Adult, pubmed-meshheading:9389914-Aged, pubmed-meshheading:9389914-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:9389914-Child, pubmed-meshheading:9389914-Combined Modality Therapy, pubmed-meshheading:9389914-Dose-Response Relationship, Drug, pubmed-meshheading:9389914-Drug Administration Schedule, pubmed-meshheading:9389914-Etoposide, pubmed-meshheading:9389914-Female, pubmed-meshheading:9389914-Granulocyte Colony-Stimulating Factor, pubmed-meshheading:9389914-Humans, pubmed-meshheading:9389914-Ifosfamide, pubmed-meshheading:9389914-Infusions, Intravenous, pubmed-meshheading:9389914-Male, pubmed-meshheading:9389914-Middle Aged, pubmed-meshheading:9389914-Recombinant Proteins, pubmed-meshheading:9389914-Sarcoma, pubmed-meshheading:9389914-Soft Tissue Neoplasms, pubmed-meshheading:9389914-Survival Rate, pubmed-meshheading:9389914-Treatment Outcome
pubmed:year
1997
pubmed:articleTitle
Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study.
pubmed:affiliation
Department of Oncology, Norwegian Radium Hospital, Montebello, Oslo, Norway.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II